Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03527147
Title Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acerta Pharma BV

non-Hodgkin lymphoma


Acalabrutinib + AZD9150

Acalabrutinib + AZD6738

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.